Connect Biopharma Holdings Ltd CNTB

US Biotechnology

$1.08 ▼ -1.82% ($-0.02)

🔥 High Short Interest

Open $1.09

Prev Close $1.10

Day Range $1.06 – $1.12

52W Range $1.06 – $3.82

Market Cap $68.01M

Beta 0.01

EPS (TTM) $-1.20

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-03-19
Shares Out.	62,960,000
Website	connectbiopharm.com ↗
Phone	18587271040
Employees	64
Revenue	$2.8M
Gross Profit	$2.8M
Net Income	-$17.3M
Free Cash Flow	-$60.6M
Total Assets	$43.5M
Total Liabilities	$16.6M
Equity	$26.9M

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Connect Biopharma Holdings Ltd is a publicly traded company under the ticker symbol CNTB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.